New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 18, 2012
12:28 EDTARB, NLSN, SWHC, RGR, GALE, GTATOn The Fly: Midday Wrap
Stocks on Wall Street were markedly higher at midday as optimism surrounding the fiscal cliff negotiations continues to spur buying. Investors have been paying less attention to recent economic reports to focus instead on the fiscal cliff, as demonstrated by the NAHB Housing Market index prompting little reaction, despite its highest reading since April 2006. The averages moved to session highs following comments from both sides of Washington's negotiating table that they hope a deal can still be reached... ECONOMIC EVENTS: In the U.S., the National Association of Home Builders index of builder confidence increased to 47, as was forecast. Also, the current-account deficit in the U.S. narrowed in the third quarter to $107.5B from a $118.1B shortfall in the prior quarter. Economists expected the deficit would narrow to about $103B... COMPANY NEWS: Gunmakers Smith & Wesson (SWHC) and Sturm, Ruger (RGR) continued their recent weakness as a Wall Street Journal cover story highlighted some of the ways American companies are distancing themselves from guns and their makers amid a public outcry in the aftermath of last week's tragedy in Connecticut. Among the recent developments underscored was the decision from private equity firm Cerberus Capital Management to put gunmaker Freedom Group up for sale... MAJOR MOVERS: Among the notable gainers was Arbitron (ARB), up over 23% after agreeing to be bought by Nielsen (NLSN) for $48 per share in cash. Shares of acquirer Nielsen also rose about 3%. Among the noteworthy losers was Galena Biopharma (GALE), down 17% after it sold common stock and warrants to purchase additional shares in a public offering. Also lower was GT Advanced Technologies (GTAT), which was downgraded at Raymond James and Stifel Nicolaus and saw its shares slide more than 12% after issuing guidance well below Street expectations... INDICES: Near noon, the Dow was up 83.20, or 0.63%, to 13,318.59; the Nasdaq was up 33.89, or 1.13%, to 3,044.49; and the S&P 500 was up 11.60, or 0.81%, to 1,441.96.
News For ARB;NLSN;SWHC;RGR;GALE;GTAT From The Last 14 Days
Check below for free stories on ARB;NLSN;SWHC;RGR;GALE;GTAT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 31, 2014
10:28 EDTGTATVerizon to launch sapphire display phone with Kyocera, SlashGear reports
Verizon (VZ) will launch Kyocera's newly unveiled Brigadier smartphone, which will feature a "near indestructible" Sapphire Shield display, reported SlashGear. Note that Apple's (AAPL) next iPhone 6 has been widely rumored to feature a sapphire display and that GT Advanced (GTAT) and Rubicon (RBCN) are sapphire suppliers. Reference Link
08:03 EDTNLSNNielsen management to meet with Deutsche Bank
Subscribe for More Information
July 29, 2014
17:27 EDTRGRSturm, Ruger declares quarterly dividend of 45c per share
Subscribe for More Information
17:26 EDTRGRSturm, Ruger raises share repurchase authorization to $100M from $25M
Subscribe for More Information
17:23 EDTRGRSturm, Ruger reports Q2 EPS $1.12, consensus $1.23
Reports Q2 revenue $153.7M, consensus $168.73M. CEO Michael O. Fifer made the following observations related to the company’s Q2 performance, "Our sales decreased 14% from the 2Q13 due to a reduction in demand for firearms and accessories. Our earnings decreased 31% and our EBITDA decreased 25%, from 2Q13. The main drivers of the reduced operating margins were the reduced sales volume, a product mix shift away from unusually strong sales of higher-margin firearms accessories last year, and increased depreciation expense. New products represented $57.1M or 18% of firearm sales in the first half of 2014."
14:54 EDTNLSNNielsen weakness a buying opportunity, says Morgan Stanley
Subscribe for More Information
13:44 EDTGTATGT Advanced shares defended at Stifel
10:52 EDTGTATApple iPhone 6 with sapphire to be limited by production issues, LEDinside says
Analysis of Apple's (AAPL) iPhone 6 supply chain indicates component suppliers have to start shipping products to OEMs for assembly in June to meet the September launch date, but LEDinside said its research did not discover demands for smartphone cover glass. "The sapphire glass version iPhone 6 will be issued in limited volumes this year," the periodical contends. Note that GT Advanced is a parter to Apple and sapphire supplier to the tech giant. Reference Link
07:04 EDTNLSNNielsen reports Q2 adjusted EPS 62c, consensus 61c
Subscribe for More Information
July 28, 2014
15:47 EDTNLSNNotable companies reporting before tomorrow's open
Subscribe for More Information
12:35 EDTSWHCSmith & Wesson announces $2M settlement agreement with SEC
Subscribe for More Information
11:14 EDTSWHCSmith & Wesson to pay $2M to settle SEC charges
Subscribe for More Information
10:22 EDTGTATMIT Technology Review discusses new sapphire production at GT
Subscribe for More Information
July 22, 2014
15:46 EDTGALEGalena in-license of Zuplenz makes sense, says Piper Jaffray
Subscribe for More Information
09:55 EDTGALEGalena 'stands little chance' of improving Zuplenz sales, TheStreet says
After Galena BioPharma entered into a license agreement with MonoSol Rx for Zuplenz, TheStreet's Adam Feuerstein predicted that the company "stands little chance of delivering higher sales of Zuplenz than its previous marketer," calling the drug one that "no one wants" and "something to promote while waiting for the phase III study of NeuVax in breast cancer to inevitably fail." Reference Link
09:03 EDTNLSNNielsen, Pointlogic announce alliance
Subscribe for More Information
07:21 EDTGALEGalena enters into licensing agreement with MonoSol Rx
MonoSol Rx announced that it has licensed Zuplenz to Galena Biopharma. Zuplenz is an oral soluble film, or OSF, for the prevention of chemotherapy-induced, radiotherapy-induced, and postoperative nausea and vomiting. The licensing agreement includes an undisclosed upfront payment from Galena, as well as double digit royalty payments from sales of Zuplenz. Zuplenz is the first oral soluble lingual film product approved by the FDA as a prescription medication, based on MonoSol Rx's proprietary PharmFilm technology.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use